Browse the evidence

Strategic dietary modulation, particularly a marked reduction in LA intake, may restore mitochondrial redox homeostasis and improve metabolic health.

Reducing linoleic acid in the diet could enhance mitochondrial function and overall metabolic health.

GLP-1ra users have similar postoperative outcomes following body contouring surgery compared to non-GLP-1ra controls.

Practitioners can consider GLP-1ra use as not adversely affecting postoperative outcomes in body contouring surgeries.

Postoperative cellulitis occurred less frequently among GLP-1ra users in matched cohorts.

GLP-1ra use may be associated with a lower risk of postoperative cellulitis.

Wound dehiscence is more prevalent among patients taking GLP-1ras for diabetes compared to those using it for weight loss.

Consideration of the indication for GLP-1ra use may be important in assessing surgical risk.

One-year discontinuation rates for GLP-1 receptor agonists can be as high as 74% in real-world studies.

Healthcare providers should be aware of the high discontinuation rates of GLP-1 RAs in real-world settings.

The percent kilocalories from carbohydrate was higher in the omnivorous group compared to the vegan group.

Omnivorous diets may provide a higher carbohydrate intake compared to vegan diets, which could influence overall energy balance.

Clinical trials of tirzepatide have demonstrated cardiovascular safety in high-risk patients.

Tirzepatide may be considered safe for use in patients at high cardiovascular risk.

The cardiovascular benefits of dual GLP-1/GIP receptor agonists like tirzepatide remain uncertain.

Further research is needed to clarify the cardiovascular benefits of tirzepatide.

There is an ongoing debate over the role of pharmacotherapy versus interventional approaches in treating obesity and MASLD in liver transplantation.

Clinicians should stay informed about evolving treatment options for obesity and MASLD.

Global consumption of ultra-processed foods (UPFs) has increased dramatically.

Practitioners should be aware of the rising trend in UPF consumption.

No additional benefits were observed for ∑MT.

Practitioners should note that increasing volume may not benefit all measures of training outcomes.

Long-term cardiovascular outcome data for recent anti-obesity medications remain inconclusive or lacking.

Practitioners should be cautious and consider the lack of long-term data when prescribing these medications.

Moorehead-Ardelt scores were higher in the bypass group at 2 years but showed no statistically significant differences later on.

Practitioners should note that while bypass may improve certain quality of life metrics initially, this effect may not persist long-term.

There is a significant multiplicative interaction of cardiovascular autonomic neuropathy (CAN) and sex on both mortality outcomes.

Understanding the interaction between CAN and sex can improve risk assessment and management strategies in diabetes care.

Most adverse events (AEs) associated with incretin-based therapies (IBTs) are mild or moderate and mainly occur during dose escalation.

Clinicians should monitor patients for mild to moderate AEs, especially during dose increases.

Only 2 out of 41 studies (approximately 5%) reported or assessed dietary intake or evaluated diet changes secondary to GLP-1/GIP RA medication use.

Practitioners should be aware of the lack of dietary assessment in studies involving GLP-1/GIP medications.

The quality of dietary assessment methods used in the studies was categorized as 'poor' and 'acceptable'.

Practitioners should consider the quality of dietary assessment methods when interpreting study results.

The review highlights a major gap in the evidence requiring urgent attention for high-quality research on dietary impacts of GLP-1/GIP medications.

There is a critical need for more rigorous studies to assess dietary changes associated with these medications.

The intervention subjects lost more weight than the control subjects (-4.1 kg vs -2.1 kg), but the difference was not statistically significant (p = 0.22).

Practitioners may consider remote dietitian support for weight loss in patients before joint surgery.

The intervention subjects had higher odds of achieving a BMI of <40 kg/m 2 (odds ratio = 1.9), but this was not statistically significant (p = 0.44).

Practitioners may find that remote interventions can help some patients achieve a healthier BMI before surgery.

There has been limited success in curbing the incidence of T2D despite lifestyle modification being standard care.

Practitioners should recognize the barriers to effective lifestyle interventions.

PA may not be a critical factor influencing weight maintenance in PWD.

Weight maintenance strategies for PWD may need to consider factors beyond just physical activity.

The evidence supporting GLP-1RAs for treating PsO and PsA remains limited.

Further clinical research is needed to establish the efficacy and safety of GLP-1RAs for PsO and PsA.

High-dose canagliflozin (300 mg/day) is significantly associated with reduced sepsis risk versus control.

Practitioners may consider high-dose canagliflozin as a safer option regarding sepsis risk.